Last reviewed · How we verify
NCT07451873: GlikoOxEND
Glycocalyx and Oxidative Stress in Endothelial Function (Part 2)
trial in Coronary Heart Disease in 35 participants. Currently enrolling.
30 September 2029
Quick facts
| Lead sponsor | Josip Juraj Strossmayer University of Osijek |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 35 |
| Start date | 1 October 2025 |
| Primary completion | 30 September 2029 |
| Estimated completion | 30 September 2029 |
| Sites | 1 location across Croatia |
Conditions studied
- Coronary Heart Disease — all drugs for Coronary Heart Disease →
Sponsor
Josip Juraj Strossmayer University of Osijek
Who can join
18 and older, any sex, with Coronary Heart Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary research objective of the project is to determine the role of eGC in microvascular reactivity in patients with coronary heart disease (CHD) before and after bypass grafting (cross-sectional study 2).The main objective of the project is to increase the excellence and interdisciplinarity of scientific work at MEFOS by connecting researchers from different scientific fields, improving conditions and resources for scientific work, and increasing international cooperation, in line with strategic objective 1: raising scientific excellence. The results of the project could provide pathophysiological insight into the development and maintenance of endothelial dysfunction in CVD, as well as identify new biomarkers for CVD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07451873
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Heart Disease
Currently open trials in the same condition.
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
- NCT07110415 — Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by · Phase 4 · recruiting
- NCT07118930 — Study of Sivelestat Sodium in OPCABG · Phase 2 · recruiting
- NCT06941792 — Inclisiran Effectiveness in China: a Pragmatic Randomized Trial · Phase 4 · active not recruiting
Other Josip Juraj Strossmayer University of Osijek trials
Trials by the same sponsor.
- NCT07437729 — Glycocalyx and Oxidative Stress in Endothelial Function (Part 1) · recruiting
- NCT06545812 — Immune Response During the Conservative and Minimal Invasive Treatment of Pain Caused by Lumbar Disc Herniation · NA · completed
- NCT06316271 — Endothelial Function in Prehypertension · not yet recruiting
- NCT06316284 — miRNA in Chronic Kidney Diseases · not yet recruiting
- NCT07269197 — Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07451873 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Josip Juraj Strossmayer University of Osijek
- Last refreshed: 9 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07451873.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing